AI in Cancer Diagnosis Market Size Overview:
Get More Information on AI in Cancer Diagnosis Market - Request Sample Report
The AI in Cancer Diagnosis Market Size was valued at USD 960.1 Million in 2023 and is expected to reach USD 2456.0 Million by 2032 and grow at a CAGR of 11.0% over the forecast period of 2024-2032.
The AI in cancer diagnosis market is growing at a very rapid rate due to the increasing incidence of cancer, advancement in diagnostic technology, and increased need for early and accurate detection. Technological innovations, particularly in AI, revolutionize cancer care through improvements in diagnostics and healthcare infrastructure. Further driving the growth of the market is investments in R&D. For example, the company launched Tempus+ in October 2022, an AI-powered program that mines real-world data for precision oncology research, and among the institutions participating in the said program are Baylor College of Medicine and Stanford Cancer Center. Some key developments in the industry include the U.S. FDA's approval of DermaSensor in January 2024, the world's first AI medical device for skin cancer detection.
The future promises research breakthroughs in AI in cancer care, promising great things in early detection and even precision medicine to usher in the customized treatment approach. Its ability to handle vast volumes of data but discern very complex patterns would transform the diagnosis of cancer and its treatment, thus highly enhancing outcomes while ensuring effectiveness in healthcare delivery. Recently polled researchers say that they believe cancer radiology and pathology will be one of the greatest beneficiaries over the next 10 years, but gynecology will be one of the worst. AI's role in pathology--and particularly in the area of handling large data sets and possibly improving the accuracy of diagnosis--is increasingly being acknowledged. The 2022 study highlighted the effectiveness of AI in detecting mammographic abnormalities while increasing diagnostic precision was obtained with a concomitant decrease in the workload of pathologists.
| Report Attributes | Details | Focus Area |
|---|---|---|
|
IBM Watson for Oncology |
Analyzes medical literature and patient data to provide treatment recommendations. |
Treatment recommendations |
|
PathAI |
Assists pathologists in diagnosing cancer from histopathology slides by identifying patterns and anomalies. |
Histopathology |
|
Google Health's DeepMind |
Uses AI to analyze medical images for early cancer detection, such as breast cancer and eye diseases. |
Medical imaging |
|
Tempus |
Analyzes clinical and molecular data to personalize cancer treatments based on genetic profiles. |
Personalized treatment |
|
Aiforia |
AI-powered imaging analysis for identifying tumor types and characteristics from pathology slides. |
Digital pathology |
|
Qure.ai |
Applies deep learning to analyze medical images, like chest X-rays and CT scans, for detecting cancer-related abnormalities. |
Medical imaging |
|
Pathologist AI |
Offers digital pathology tools for detecting cancerous tissues and lesions in biopsy samples. |
Digital pathology |
|
Kheiron Medical Technologies |
AI for breast cancer screening, assisting radiologists in interpreting mammograms. |
Breast cancer screening |
|
Freenome |
Uses AI to analyze blood samples for cancer biomarkers, aiming for early detection through liquid biopsies. |
Liquid biopsy |
|
OncoAI |
Integrates AI with genomic data to support personalized treatment plans by predicting responses to therapies. |
Genomic data analysis and personalized treatment |
Technological developments in AI applications such as classification, detection, segmentation, and monitoring further trigger market growth. Government and private sectors are investing in enriching AI adoption in oncology. Qritive's release of QAi Prostate in March 2023 is a good example of the use of AI for the accurate diagnosis of prostate cancer, helping in tumor classification and biopsy analysis. Growth in the market is seen because of strategic collaborations and expansions undertaken by key players. Exscientia partnered with The University of Texas MD Anderson Cancer Center for small-molecule oncology therapies in November 2022. Lunit further expanded to the Middle East in July 2023, which is another AI-driven solution that covers every region around the world. For instance, regulatory frameworks, such as the European Commission's initial AI regulations published in April 2021, would appear to give policymakers at least the comfort of ensuring matters remained ethical and secure data altogether while leaving space to innovate more in the AI in the cancer diagnosis market.
AI in Cancer Diagnosis Market Dynamics
Drivers
The increased importance of early detection of cancers grows the AI in the cancer diagnostics market. As early detection significantly contributes toward lowering cancer-associated mortality, timely treatment and better long-term survival rates are allowed through this process. This is increased by using AI algorithms that can analyze medical imaging data, such as CT scans, MRI scans, and pathology slides, with a high degree of precision and time efficiency. These tools minimize the chances of diagnostic errors, initiate timely treatments, and hence improve patient outcomes and lower healthcare costs. Increased awareness about the benefits of early detection is expected to translate to increased demand for AI-powered diagnostic solutions.
The demand for software solutions in this sector is also growing. In 2022, software solutions make up the largest market share because they can process and analyze large complex datasets. AI-powered software is much more important to developing and deploying machine learning and deep learning algorithms, integration with existing healthcare systems, and delivery of continuous updates, leading to increasing diagnostics accuracy and efficiency.
Rising cases of breast cancer also boost growth in the market. Close to 2.3 million women were diagnosed in 2020, while around 685,000 died, making the demand for accurate diagnostic tools critical. Further refining the accuracy of mammogram analyses, AI technologies such as computer-aided detection (CAD) systems can also support personalized screening approaches by analyzing patient-level data. Perhaps, the prime motivation here is the need for AI-assisted screening and diagnosis, while advancement in the detection of cancer in its early stages is something that calls for precise and fast diagnosis. Diagnostic centers form an integral part of this market as they are increasing their reach through the smart usage of AI tools and electronic health record systems.
Restraints
AI in Cancer Diagnosis Market Segmentation Analysis
By Component
Hardware components accounted for the highest revenue share of 39.6% in the market in 2023. The reason this one tops the list is that AI technology adoption has been seen by the manufacturers of medical devices to further improve patient care. An important characteristic of AI in medical devices is their ability to learn and improve from experience and real-world data. Hence, several major players are focusing on the development and improvement of AI-based cancer therapy solutions. In addition, government initiatives drive the AI-based medical devices market. For instance, in January 2021, the FDA in the United States published an action plan on AI/ML-based SaMD to support the regulation of innovative medical devices and digital health technologies.
The CAGR for the segment of software solutions from 2024 to 2032 is expected to be the highest. Growth rates are attributed to adoption in oncology by healthcare providers and payers mainly in AI software solutions. AI software solutions find great application in the prediction of various cancers, including brain, breast, liver, lung, and prostate. Consequently, many of the key participants have focused on developing and launching new equipment and software, which, in turn, makes the competition in the market even more challenging. For instance, in October 2023, Philips collaborated with Quibim, the company committed to imaging biomarkers, for the launch of AI-driven imaging and reporting solutions for MR prostate scans.
By Cancer Type
The most significant type of cancer in terms of revenue for 2023 was breast cancer. This market segment is fueled by the growing incidence of breast cancer globally. According to a release by the American Society of Clinical Oncology, in 2020, estimated new cases of cancer were approximately 2,261,419, and the highest occurrence was reported in the U.S, which is likely to have an estimated 297,790 new cases of breast cancer in 2023. The increasing number of breast cancer cases is propelling further demand for high-tech solutions in the market, and this factor is enhancing growth.
The prostate cancer segment is likely to experience the highest CAGR of 29.9% during the forecast period. According to CDC statistics, prostate cancer affects approximately 13 out of every 100 men in the U.S. In 2023, the National Cancer Institute estimated that new cases of prostate cancer totaled around 288,300, and growing this market through new services and products is the strategy of companies operating in this category. For example, in January 2024, Quibim enhanced its AI-based prostate cancer solutions by releasing QP-Prostate, its AI-based detection tool, which ensures accuracy, and quality, and shortens the time for processing by the end.
By End User
The hospitals segment occupied a substantial share of 48.2% in 2023, while the outpatient clinics segment was the next. The market in this segment is largely driven by higher adoption of AI-powered solutions in hospitals, increased companies' entry into the market to provide services across cancer care within these establishments, and encouraging patients' feedback. The hospital segment will grow aggressively throughout the forecast period.
Additionally, this sector is expected to experience the highest CAGR during the forecast period due to the latest healthcare-specific technological advancements. Digitalization, AI, VR, and immersive technologies have revolutionized testing, treatment, and data acquisition processes in hospitals. In addition, hospitals are increasingly using AI-based algorithms in cancer treatment to provide an accurate diagnosis with a lower probability of misdiagnosis.
AI in Cancer Diagnosis Regional Outlook
North America North America led the AI in the cancer diagnosis market with a commanding revenue share of 43.6% in 2023. This dominance is attributed to the region's advanced digital infrastructure, supportive regulatory and reimbursement policies, and proactive government initiatives promoting AI technology adoption in healthcare. The rising incidence of various cancers is fueling the demand for advanced diagnostics and therapeutics, further driving market growth. In November 2021, Sanofi's collaboration with Owkin Inc. and its investment of USD 180 million in AI advancements for oncology underscore the region's commitment to innovation.
The Asia Pacific region is anticipated to experience the highest CAGR in the AI in cancer diagnosis market during the forecast period. This growth is driven by the increasing adoption of digitalization in diagnostic laboratories and hospitals, a growing elderly population, and a rising prevalence of cancer. According to Globocan, Asia-Pacific accounted for 9.7 million of the 19 million new cancer cases reported globally in 2020. Key initiatives, such as GE Healthcare's collaboration with the National Cancer Centre Singapore in June 2022, aim to leverage AI to enhance cancer care in the region.
China holds the largest revenue share of 22.6% in the Asia Pacific AI in the cancer diagnosis market. Ongoing research in machine learning, image analysis, and data processing is improving the accuracy and efficiency of AI applications in oncology. These research efforts are facilitating the integration of AI into clinical practices and healthcare systems.
Need any customization research on AI in Cancer Diagnosis Market - Enquiry Now
Azra AI
IBM
Siemens Healthcare GmbH
Intel Corporation
GE HealthCare
NVIDIA Corporation
Digital Diagnostics Inc.
ConcertAI
Median Technologies
PathAI
EarlySign
Cancer Center.ai
Microsoft
Flatiron
Path AI
Therapixel
Tempus
Paige Ai, Inc
Kheiron Medical Technologies Limited
SkinVision and others.
Recent Developments
In January 2024, NVIDIA Corporation joined forces with Deepcell to advance the application of generative AI in single-cell research, focusing on stem cells, cancer, and cell therapies.
In January 2024, PathAI expanded its PathExplore platform by introducing six new oncology indications. This AI-powered pathology panel is designed for the spatial analysis of the tumor microenvironment (TME).
In December 2023, ConcertAI acquired CancerLinQ, a former subsidiary of the American Society of Clinical Oncology (ASCO). Alongside this acquisition, ASCO entered into a multiyear collaboration agreement with CancerLinQ. This partnership aims to enhance CancerLinQ’s mission—originally launched by ASCO in 2013—to advance cancer care and accelerate clinical research. The new venture will utilize real-world data, analytics, next-generation AI, and other advanced technologies to further develop CancerLinQ’s capabilities.
| Report Attributes | Details |
| Market Size in 2023 | US$ 960.1 Million |
| Market Size by 2032 | US$ 2456.0 Million |
| CAGR | CAGR of 11.0% From 2024 to 2032 |
| Base Year | 2023 |
| Forecast Period | 2024-2032 |
| Historical Data | 2020-2022 |
| Report Scope & Coverage | Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
| Key Segments | • By Component Outlook (Software Solutions, Hardware, Services) • By Cancer Type (Breast cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Brain Tumor, Others) • By End User (Hospitals, Surgical Centers and Medical Institutes, Others) |
| Regional Analysis/Coverage | North America (USA, Canada, Mexico), Europe (Germany, UK, France, Italy, Spain, Netherlands, Rest of Europe), Asia-Pacific (Japan, South Korea, China, India, Australia, Rest of Asia-Pacific), The Middle East & Africa (Israel, UAE, South Africa, Rest of Middle East & Africa), Latin America (Brazil, Argentina, Rest of Latin America) |
| Company Profiles | Azra AI, IBM, Siemens Healthcare GmbH, Intel Corporation, GE HealthCare, NVIDIA Corporation, Digital Diagnostics Inc., ConcertAI, Median Technologies, PathAI, EarlySign and others |
| Key Drivers | • Early Detection, Software Advancements, and Breast Cancer Prevalence |
| Market Restraints | • High Implementation Costs • Data Privacy and Security Concerns |
Ans: The AI in Cancer Diagnosis Market size was valued at US$ 960.1 Million in 2023.
Ans: North America will dominate the region because of the number of rising cancer patients in these regions and also the rising demand for the Ai in cancer diagnoses
Ans: The AI in Cancer Diagnosis Market is growing at a CAGR of 11.0% Over the Forecast Period 2024-2032.
Ans: Market is divided in 3 segments by component outlook, by cancer type and by end user.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Adoption Rates, 2023
5.2 User Demographics, By User Type and Roles, 2023
5.3 Feature Analysis, by Feature Type
5.4 Cost Analysis, by Software
5.5 Integration Capabilities
5.6 Regulatory Compliance, by Region
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Product Benchmarking
6.3.1 Product specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Product launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. AI in Cancer Diagnosis Market Segmentation, by Component
7.1 Chapter Overview
7.2 Software Solutions
7.2.1 Software Solutions Market Trends Analysis (2020-2032)
7.2.2 Software Solutions Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Hardware
7.3.1 Hardware Market Trends Analysis (2020-2032)
7.3.2 Hardware Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Services
7.4.1 Services Market Trends Analysis (2020-2032)
7.4.2 Services Market Size Estimates and Forecasts to 2032 (USD Billion)
8. AI in Cancer Diagnosis Market Segmentation, by Cancer Type
8.1 Chapter Overview
8.2 Breast Cancer
8.2.1 Breast Cancer Market Trends Analysis (2020-2032)
8.2.2 Breast Cancer Market Size Estimates and Forecasts to 2032 (USD Million)
8.3 Lung Cancer
8.3.1 Lung Cancer Market Trends Analysis (2020-2032)
8.3.2 Lung Cancer Market Size Estimates and Forecasts to 2032 (USD Million)
8.4 Prostate Cancer
8.4.1 Prostate Cancer Market Trends Analysis (2020-2032)
8.4.2 Prostate Cancer Market Size Estimates and Forecasts to 2032 (USD Million)
8.5 Colorectal Cancer
8.5.1 Colorectal Cancer Market Trends Analysis (2020-2032)
8.5.2 Colorectal Cancer Market Size Estimates and Forecasts to 2032 (USD Million)
8.6 Brain Tumor
8.6.1 Brain Tumor Market Trends Analysis (2020-2032)
8.6.2 Brain Tumor Market Size Estimates and Forecasts to 2032 (USD Million)
8.7 Others
8.7.1 Others Market Trends Analysis (2020-2032)
8.7.2 Others Market Size Estimates and Forecasts to 2032 (USD Million)
9. AI in Cancer Diagnosis Market Segmentation, by End User
9.1 Chapter Overview
9.2 Hospitals
9.2.1 Hospitals Market Trends Analysis (2020-2032)
9.2.2 Hospitals Market Size Estimates and Forecasts to 2032 (USD Million)
9.3 Surgical Centers & Medical Institutes
9.3.1 Surgical Centers & Medical Institutes Market Trends Analysis (2020-2032)
9.3.2 Surgical Centers & Medical Institutes Market Size Estimates and Forecasts to 2032 (USD Million)
9.4 Others
9.4.1 Others Market Trends Analysis (2020-2032)
9.4.2 Others Market Size Estimates and Forecasts to 2032 (USD Million)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America AI in Cancer Diagnosis Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.2.3 North America AI in Cancer Diagnosis Market Estimates and Forecasts, by Component (2020-2032) (USD Million)
10.2.4 North America AI in Cancer Diagnosis Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Million)
10.2.5 North America AI in Cancer Diagnosis Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.2.6 USA
10.2.6.1 USA AI in Cancer Diagnosis Market Estimates and Forecasts, by Component (2020-2032) (USD Million)
10.2.6.2 USA AI in Cancer Diagnosis Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Million)
10.2.6.3 USA AI in Cancer Diagnosis Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.2.7 Canada
10.2.7.1 Canada AI in Cancer Diagnosis Market Estimates and Forecasts, by Component (2020-2032) (USD Million)
10.2.7.2 Canada AI in Cancer Diagnosis Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Million)
10.2.7.3 Canada AI in Cancer Diagnosis Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.2.8 Mexico
10.2.8.1 Mexico AI in Cancer Diagnosis Market Estimates and Forecasts, by Component (2020-2032) (USD Million)
10.2.8.2 Mexico AI in Cancer Diagnosis Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Million)
10.2.8.3 Mexico AI in Cancer Diagnosis Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3 Europe
10.3.1 Eastern Europe
10.3.1.1 Trends Analysis
10.3.1.2 Eastern Europe AI in Cancer Diagnosis Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.3.1.3 Eastern Europe AI in Cancer Diagnosis Market Estimates and Forecasts, by Component (2020-2032) (USD Million)
10.3.1.4 Eastern Europe AI in Cancer Diagnosis Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Million)
10.3.1.5 Eastern Europe AI in Cancer Diagnosis Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.1.6 Poland
10.3.1.6.1 Poland AI in Cancer Diagnosis Market Estimates and Forecasts, by Component (2020-2032) (USD Million)
10.3.1.6.2 Poland AI in Cancer Diagnosis Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Million)
10.3.1.6.3 Poland AI in Cancer Diagnosis Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.1.7 Romania
10.3.1.7.1 Romania AI in Cancer Diagnosis Market Estimates and Forecasts, by Component (2020-2032) (USD Million)
10.3.1.7.2 Romania AI in Cancer Diagnosis Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Million)
10.3.1.7.3 Romania AI in Cancer Diagnosis Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.1.8 Hungary
10.3.1.8.1 Hungary AI in Cancer Diagnosis Market Estimates and Forecasts, by Component (2020-2032) (USD Million)
10.3.1.8.2 Hungary AI in Cancer Diagnosis Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Million)
10.3.1.8.3 Hungary AI in Cancer Diagnosis Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.1.9 turkey
10.3.1.9.1 Turkey AI in Cancer Diagnosis Market Estimates and Forecasts, by Component (2020-2032) (USD Million)
10.3.1.9.2 Turkey AI in Cancer Diagnosis Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Million)
10.3.1.9.3 Turkey AI in Cancer Diagnosis Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.1.10 Rest of Eastern Europe
10.3.1.10.1 Rest of Eastern Europe AI in Cancer Diagnosis Market Estimates and Forecasts, by Component (2020-2032) (USD Million)
10.3.1.10.2 Rest of Eastern Europe AI in Cancer Diagnosis Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Million)
10.3.1.10.3 Rest of Eastern Europe AI in Cancer Diagnosis Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2 Western Europe
10.3.2.1 Trends Analysis
10.3.2.2 Western Europe AI in Cancer Diagnosis Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.3.2.3 Western Europe AI in Cancer Diagnosis Market Estimates and Forecasts, by Component (2020-2032) (USD Million)
10.3.2.4 Western Europe AI in Cancer Diagnosis Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Million)
10.3.2.5 Western Europe AI in Cancer Diagnosis Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.6 Germany
10.3.2.6.1 Germany AI in Cancer Diagnosis Market Estimates and Forecasts, by Component (2020-2032) (USD Million)
10.3.2.6.2 Germany AI in Cancer Diagnosis Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Million)
10.3.2.6.3 Germany AI in Cancer Diagnosis Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.7 France
10.3.2.7.1 France AI in Cancer Diagnosis Market Estimates and Forecasts, by Component (2020-2032) (USD Million)
10.3.2.7.2 France AI in Cancer Diagnosis Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Million)
10.3.2.7.3 France AI in Cancer Diagnosis Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.8 UK
10.3.2.8.1 UK AI in Cancer Diagnosis Market Estimates and Forecasts, by Component (2020-2032) (USD Million)
10.3.2.8.2 UK AI in Cancer Diagnosis Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Million)
10.3.2.8.3 UK AI in Cancer Diagnosis Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.9 Italy
10.3.2.9.1 Italy AI in Cancer Diagnosis Market Estimates and Forecasts, by Component (2020-2032) (USD Million)
10.3.2.9.2 Italy AI in Cancer Diagnosis Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Million)
10.3.2.9.3 Italy AI in Cancer Diagnosis Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.10 Spain
10.3.2.10.1 Spain AI in Cancer Diagnosis Market Estimates and Forecasts, by Component (2020-2032) (USD Million)
10.3.2.10.2 Spain AI in Cancer Diagnosis Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Million)
10.3.2.10.3 Spain AI in Cancer Diagnosis Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.11 Netherlands
10.3.2.11.1 Netherlands AI in Cancer Diagnosis Market Estimates and Forecasts, by Component (2020-2032) (USD Million)
10.3.2.11.2 Netherlands AI in Cancer Diagnosis Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Million)
10.3.2.11.3 Netherlands AI in Cancer Diagnosis Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.12 Switzerland
10.3.2.12.1 Switzerland AI in Cancer Diagnosis Market Estimates and Forecasts, by Component (2020-2032) (USD Million)
10.3.2.12.2 Switzerland AI in Cancer Diagnosis Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Million)
10.3.2.12.3 Switzerland AI in Cancer Diagnosis Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.13 Austria
10.3.2.13.1 Austria AI in Cancer Diagnosis Market Estimates and Forecasts, by Component (2020-2032) (USD Million)
10.3.2.13.2 Austria AI in Cancer Diagnosis Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Million)
10.3.2.13.3 Austria AI in Cancer Diagnosis Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.3.2.14 Rest of Western Europe
10.3.2.14.1 Rest of Western Europe AI in Cancer Diagnosis Market Estimates and Forecasts, by Component (2020-2032) (USD Million)
10.3.2.14.2 Rest of Western Europe AI in Cancer Diagnosis Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Million)
10.3.2.14.3 Rest of Western Europe AI in Cancer Diagnosis Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific AI in Cancer Diagnosis Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.4.3 Asia Pacific AI in Cancer Diagnosis Market Estimates and Forecasts, by Component (2020-2032) (USD Million)
10.4.4 Asia Pacific AI in Cancer Diagnosis Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Million)
10.4.5 Asia Pacific AI in Cancer Diagnosis Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.6 China
10.4.6.1 China AI in Cancer Diagnosis Market Estimates and Forecasts, by Component (2020-2032) (USD Million)
10.4.6.2 China AI in Cancer Diagnosis Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Million)
10.4.6.3 China AI in Cancer Diagnosis Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.7 India
10.4.7.1 India AI in Cancer Diagnosis Market Estimates and Forecasts, by Component (2020-2032) (USD Million)
10.4.7.2 India AI in Cancer Diagnosis Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Million)
10.4.7.3 India AI in Cancer Diagnosis Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.8 Japan
10.4.8.1 Japan AI in Cancer Diagnosis Market Estimates and Forecasts, by Component (2020-2032) (USD Million)
10.4.8.2 Japan AI in Cancer Diagnosis Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Million)
10.4.8.3 Japan AI in Cancer Diagnosis Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.9 South Korea
10.4.9.1 South Korea AI in Cancer Diagnosis Market Estimates and Forecasts, by Component (2020-2032) (USD Million)
10.4.9.2 South Korea AI in Cancer Diagnosis Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Million)
10.4.9.3 South Korea AI in Cancer Diagnosis Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.10 Vietnam
10.4.10.1 Vietnam AI in Cancer Diagnosis Market Estimates and Forecasts, by Component (2020-2032) (USD Million)
10.4.10.2 Vietnam AI in Cancer Diagnosis Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Million)
10.4.10.3 Vietnam AI in Cancer Diagnosis Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.11 Singapore
10.4.11.1 Singapore AI in Cancer Diagnosis Market Estimates and Forecasts, by Component (2020-2032) (USD Million)
10.4.11.2 Singapore AI in Cancer Diagnosis Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Million)
10.4.11.3 Singapore AI in Cancer Diagnosis Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.12 Australia
10.4.12.1 Australia AI in Cancer Diagnosis Market Estimates and Forecasts, by Component (2020-2032) (USD Million)
10.4.12.2 Australia AI in Cancer Diagnosis Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Million)
10.4.12.3 Australia AI in Cancer Diagnosis Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.4.13 Rest of Asia Pacific
10.4.13.1 Rest of Asia Pacific AI in Cancer Diagnosis Market Estimates and Forecasts, by Component (2020-2032) (USD Million)
10.4.13.2 Rest of Asia Pacific AI in Cancer Diagnosis Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Million)
10.4.13.3 Rest of Asia Pacific AI in Cancer Diagnosis Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5 Middle East and Africa
10.5.1 Middle East
10.5.1.1 Trends Analysis
10.5.1.2 Middle East AI in Cancer Diagnosis Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.5.1.3 Middle East AI in Cancer Diagnosis Market Estimates and Forecasts, by Component (2020-2032) (USD Million)
10.5.1.4 Middle East AI in Cancer Diagnosis Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Million)
10.5.1.5 Middle East AI in Cancer Diagnosis Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.1.6 UAE
10.5.1.6.1 UAE AI in Cancer Diagnosis Market Estimates and Forecasts, by Component (2020-2032) (USD Million)
10.5.1.6.2 UAE AI in Cancer Diagnosis Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Million)
10.5.1.6.3 UAE AI in Cancer Diagnosis Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.1.7 Egypt
10.5.1.7.1 Egypt AI in Cancer Diagnosis Market Estimates and Forecasts, by Component (2020-2032) (USD Million)
10.5.1.7.2 Egypt AI in Cancer Diagnosis Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Million)
10.5.1.7.3 Egypt AI in Cancer Diagnosis Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.1.8 Saudi Arabia
10.5.1.8.1 Saudi Arabia AI in Cancer Diagnosis Market Estimates and Forecasts, by Component (2020-2032) (USD Million)
10.5.1.8.2 Saudi Arabia AI in Cancer Diagnosis Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Million)
10.5.1.8.3 Saudi Arabia AI in Cancer Diagnosis Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.1.9 Qatar
10.5.1.9.1 Qatar AI in Cancer Diagnosis Market Estimates and Forecasts, by Component (2020-2032) (USD Million)
10.5.1.9.2 Qatar AI in Cancer Diagnosis Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Million)
10.5.1.9.3 Qatar AI in Cancer Diagnosis Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.1.10 Rest of Middle East
10.5.1.10.1 Rest of Middle East AI in Cancer Diagnosis Market Estimates and Forecasts, by Component (2020-2032) (USD Million)
10.5.1.10.2 Rest of Middle East AI in Cancer Diagnosis Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Million)
10.5.1.10.3 Rest of Middle East AI in Cancer Diagnosis Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.2 Africa
10.5.2.1 Trends Analysis
10.5.2.2 Africa AI in Cancer Diagnosis Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.5.2.3 Africa AI in Cancer Diagnosis Market Estimates and Forecasts, by Component (2020-2032) (USD Million)
10.5.2.4 Africa AI in Cancer Diagnosis Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Million)
10.5.2.5 Africa AI in Cancer Diagnosis Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.2.6 South Africa
10.5.2.6.1 South Africa AI in Cancer Diagnosis Market Estimates and Forecasts, by Component (2020-2032) (USD Million)
10.5.2.6.2 South Africa AI in Cancer Diagnosis Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Million)
10.5.2.6.3 South Africa AI in Cancer Diagnosis Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.2.7 Nigeria
10.5.2.7.1 Nigeria AI in Cancer Diagnosis Market Estimates and Forecasts, by Component (2020-2032) (USD Million)
10.5.2.7.2 Nigeria AI in Cancer Diagnosis Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Million)
10.5.2.7.3 Nigeria AI in Cancer Diagnosis Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.5.2.8 Rest of Africa
10.5.2.8.1 Rest of Africa AI in Cancer Diagnosis Market Estimates and Forecasts, by Component (2020-2032) (USD Million)
10.5.2.8.2 Rest of Africa AI in Cancer Diagnosis Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Million)
10.5.2.8.3 Rest of Africa AI in Cancer Diagnosis Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America AI in Cancer Diagnosis Market Estimates and Forecasts, by Country (2020-2032) (USD Million)
10.6.3 Latin America AI in Cancer Diagnosis Market Estimates and Forecasts, by Component (2020-2032) (USD Million)
10.6.4 Latin America AI in Cancer Diagnosis Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Million)
10.6.5 Latin America AI in Cancer Diagnosis Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.6.6 Brazil
10.6.6.1 Brazil AI in Cancer Diagnosis Market Estimates and Forecasts, by Component (2020-2032) (USD Million)
10.6.6.2 Brazil AI in Cancer Diagnosis Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Million)
10.6.6.3 Brazil AI in Cancer Diagnosis Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.6.7 Argentina
10.6.7.1 Argentina AI in Cancer Diagnosis Market Estimates and Forecasts, by Component (2020-2032) (USD Million)
10.6.7.2 Argentina AI in Cancer Diagnosis Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Million)
10.6.7.3 Argentina AI in Cancer Diagnosis Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.6.8 Colombia
10.6.8.1 Colombia AI in Cancer Diagnosis Market Estimates and Forecasts, by Component (2020-2032) (USD Million)
10.6.8.2 Colombia AI in Cancer Diagnosis Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Million)
10.6.8.3 Colombia AI in Cancer Diagnosis Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
10.6.9 Rest of Latin America
10.6.9.1 Rest of Latin America AI in Cancer Diagnosis Market Estimates and Forecasts, by Component (2020-2032) (USD Million)
10.6.9.2 Rest of Latin America AI in Cancer Diagnosis Market Estimates and Forecasts, by Cancer Type (2020-2032) (USD Million)
10.6.9.3 Rest of Latin America AI in Cancer Diagnosis Market Estimates and Forecasts, by End User (2020-2032) (USD Million)
11. Company Profiles
11.1 Azra AI
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Products/ Services Offered
11.1.4 SWOT Analysis
11.2 Intel Corporation
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Products/ Services Offered
11.2.4 SWOT Analysis
11.3 IBM
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Products/ Services Offered
11.3.4 SWOT Analysis
11.4 Median Technologies
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Products/ Services Offered
11.4.4 SWOT Analysis
11.5 Cancer Center.ai
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Products/ Services Offered
11.5.4 SWOT Analysis
11.6 Kheiron Medical Technologies Limited
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Products/ Services Offered
11.6.4 SWOT Analysis
11.7 Microsoft
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Products/ Services Offered
11.7.4 SWOT Analysis
11.8 PathAI
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Products/ Services Offered
11.8.4 SWOT Analysis
11.9 NVIDIA Corporation
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Products/ Services Offered
11.9.4 SWOT Analysis
11.10 Tempus
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Products/ Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segmentation
By Component
Software Solutions
Hardware
Services
By Cancer Type
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Brain Tumor
Others
By End User
Hospitals
Surgical Centers & Medical Institutes
Others
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of the Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Product Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Product Matrix which gives a detailed comparison of the product portfolio of each company
Geographic Analysis
Additional countries in any of the regions
Company Information
Detailed analysis and profiling of additional market players (Up to five)
The Medical Robots Market Size was USD 14.9 billion in 2023 and is expected to reach USD 57.0 billion by 2032 and grow at a CAGR of 16.06% by 2024-2032.
The Wound Closure Market size was estimated USD 17.81 billion in 2023 and is expected to reach USD 28.6 billion by 2031 at a CAGR of 6.1% during the forecast period of 2024-2031.
The Healthcare Predictive Analytics Market was valued at USD 14.02 billion in 2023 and is expected to reach USD 126.15 billion by 2032, growing at a CAGR of 27.67% from 2024-2032.
The Medical Aesthetics Market Size was valued at USD 13.27 billion in 2023 and is witnessed to reach USD 31.06 billion by 2032 and grow at a CAGR of 10.55% over the forecast period 2024-2032.
The Clinical Documentation Improvement Market Size was assessed to be worth USD 5.13 billion in 2023 and is expected to increase to USD 9.96 billion by 2032.
The Radiation Oncology Treatment Planning Software Market size was estimated at USD 2.18 billion in 2023 and is expected to reach USD 4.75 billion by 2032 at a CAGR of 9.04% during the forecast period of 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
